Inside Health Policy covers our comment

Our comment to FDA about its use of the Pharmacy Compounding Advisory Committee (PCAC) was covered in detail by Inside Health Policy in “Compounding Pharmacies Say FDA Mismanages Compounding Ad Comm.”

Related posts

UK-based pharmaphorum is covering the GLP-1 issue on this side of the pond — specifically Lilly’s...

Reuters, like many other media outlets, covered Novo Nordisk’s request that the FDA add semaglutide...

San Diego’s KOGO has a short news piece on tirzepatide coming out of shortage, and its focus is on...